Advanced Filters
noise

Manhattan, New York Clinical Trials

A listing of Manhattan, New York clinical trials actively recruiting patient volunteers.

Found 2,152 clinical trials

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, …

18 years of age All Phase 1

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery. In Arm A the researchers will see …

18 years of age All Phase 2

Pilocarpine Use After Kahook Goniotomy

The goal of this study is to determine whether using pilocarpine provides added benefit to the success of combined cataract + KDB surgery.

30 - 100 years of age All Phase 3
C Cancer Clinical Trials Team

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.

18 years of age All Phase 1/2

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.

18 years of age All Phase 1
D Debra Annane, MPH

Project I Test: Implementing HIV Testing in Opioid Treatment Programs

This study will test two active evidence-based "practice coaching" (PC) interventions to improve opioid treatment programs' (OTPs') provision and sustained implementation of on-site 1) HIV testing and linkage to care and 2) HIV/Hepatitis C virus (HCV) testing and linkage to care among patients seeking/receiving substance use disorder treatment. Aims are: …

18 years of age All Phase N/A
R Rupesh Kotecha, M.D.

Cabozantinib for Patients With Recurrent or Progressive Meningioma

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

18 years of age All Phase 2
E Estefania Bobe Cortes

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

18 years of age All Phase 1/2
A Additional Contact Information

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy and safety of asciminib in newly diagnosed CML-CP. Patients will receive asciminib 80 mg orally once …

18 years of age All Phase 2
A Allyson Flower, MD

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.

1 - 50 years of age All Phase 2

Simplify language using AI